Leadership Overview
PT. Inertia Utama has 4 executives leading key functions including technology, operations, and governance.
Driven by innovation, PT. Inertia Utama operates within the pharmaceutical industry, focusing on delivering essential healthcare solutions and maintaining a strong market presence in Indonesia.
Driven by innovation, PT. Inertia Utama operates within the pharmaceutical industry, focusing on delivering essential healthcare solutions and maintaining a strong market presence in Indonesia.
Leadership Roles at PT. Inertia Utama
Hery Sutanto - President & Director
Hery Sutanto, the President & Director at PT. Inertia Utama, provides executive leadership and strategic direction for the company's pharmaceutical operations. Sutanto guides the overall business strategy, focusing on market expansion and sustainable growth within the Indonesian pharmaceutical landscape. This pivotal role involves overseeing financial performance, managing key stakeholder relationships, and ensuring the company's long-term vision is realized. Hery Sutanto champions initiatives aimed at enhancing product development pipelines and strengthening the company's competitive position. By driving strategic partnerships and fostering innovation, Sutanto directly impacts PT. Inertia Utama's ability to meet evolving healthcare needs. The President & Director also ensures that corporate governance principles are upheld, maintaining ethical standards and regulatory compliance across all business units. This comprehensive leadership ensures operational excellence and sustained profitability.
Raymond Tjandrawinata - President & Commissioner
Raymond Tjandrawinata, the President & Commissioner at PT. Inertia Utama, provides high-level oversight and strategic guidance, ensuring robust corporate governance and long-term company vision. Tjandrawinata's role involves reviewing and approving major corporate decisions, safeguarding shareholder interests, and ensuring alignment with industry best practices in the pharmaceutical sector. This executive function focuses on strategic planning and risk management, critical for navigating the complexities of the Indonesian healthcare market. Raymond Tjandrawinata also contributes to setting the company's ethical framework and ensuring compliance with all relevant regulations. By providing strategic counsel and effective oversight, Tjandrawinata directly supports PT. Inertia Utama's commitment to quality and innovation. The President & Commissioner's leadership ensures the company operates with integrity and maintains a strong foundation for future development and market leadership.
Wimala Widjaja - Chief Information Officer
Wimala Widjaja, the Chief Information Officer at PT. Inertia Utama, directs the company's technology strategy and digital transformation initiatives. Overseeing all IT infrastructure, Widjaja ensures robust cybersecurity measures and data integrity, critical for pharmaceutical operations. This leadership role involves managing the integration of new technologies to enhance operational efficiency and support research and development efforts. By optimizing the company's technological backbone, Wimala Widjaja directly contributes to PT. Inertia Utama's ability to innovate and maintain compliance within the highly regulated pharmaceutical sector. The Chief Information Officer also collaborates with other department heads to align technology roadmaps with overarching business objectives, ensuring seamless data flow and system performance across all functions. This strategic oversight guarantees that technology investments yield maximum return and support the company's growth trajectory in the Indonesian market.
Ferry Soetikno - Direktur
Ferry Soetikno, the Direktur at PT. Inertia Utama, manages key operational aspects and drives strategic execution within the pharmaceutical sector. Soetikno's responsibilities encompass overseeing daily business activities, ensuring adherence to stringent quality control standards, and optimizing production processes. This executive function involves close coordination with supply chain partners and regulatory bodies to guarantee the timely and safe delivery of pharmaceutical products. Ferry Soetikno also plays a vital role in fostering a culture of continuous improvement, identifying opportunities to enhance operational workflows and reduce costs. By focusing on efficient resource allocation and effective team management, Soetikno directly supports PT. Inertia Utama's mission to provide high-quality medicines. The Direktur's leadership ensures that operational targets are met, contributing significantly to the company's overall performance and market standing in Indonesia.
Explore Leadership Teams in Manufacturing
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
Company Leadership ES
SS
BH
Dexcel Pharma is Israel’s largest privately owned pharmaceutical company, founded in 1968 and headquartered in Or Akiva. It develops, manufactures, and commercializes value‑added branded prescription drugs, generics, and OTC products—primarily oral solid dosage forms—supplying more than 85 products in over 175 dosage forms to markets including the U.S., U.K., Germany, Austria, and others through subsidiaries and distribution partners.
Company Leadership
EH
Founded in 1973 and headquartered in Bangalore, India, Micro Lab is a pharmaceutical manufacturer, wholesaler, and R&D company.
Company Leadership MH
RK
RB
PM
Founded in 1954 and headquartered in Suresnes, France, Servier international is an independent pharmaceutical company governed by a non-profit foundation. Their three research centres are continuously involved in creating, testing, and developing new medicinal products, which are manufactured and packaged in their production centres around the world.
Company Leadership AK
VT
KP
Frequently Asked Questions Regarding PT. Inertia Utama Top Executives and Leadership Team
